Monday 10th May 2021 |
Text too small? |
Global advanced genetics seedling company, ArborGen Holdings Limited has advised of an uplift in the Company’s earnings guidance. The Company now expects US GAAP EBITDA1 to be in the US$11-11.5 million range for the fiscal year ending March 2021 (FY2021) – up from the US$10 - $11 million guidance provided in January 20212, and materially ahead of prior year comparable EBITDA of US$5.4 million. This upgraded guidance includes US$3.7 million of Covid-19 related government grant income (previously forecast to be US$2.6m). The Company estimates that the grant income received approximates the impact of lost sales due to Covid-19 (i.e. unsold seedlings) as well as incremental Covid-19 related costs incurred during the period.
In addition, net bank debt reduced to approximately US$28 million3 at year end ($30.3m as at 30 September 2020). Net debt would have been even lower but for the late lifting season brought about by restrictions on migrant labour into the US from Central America, which resulted in accounts receivable, being approximately US$2 million higher than would otherwise have been the case. Those receivables have since been collected in April 2021. The main use of cash during the period was a US$2.5 million spend on building our supply of higher value MCP seed inventory in the US, which will be available for sale in FY2022 and FY2023.
Commenting on the Company prospects for the new fiscal year, ArborGen’s Chairman, David Knott said “While FY2021 was a very challenging year with Covid-19 materially impacting sales in two of the three regions in which we operate, looking ahead, increased availability of our proprietary MCP seedlings in the US, improving markets in all regions, and higher demand for our proprietary genetics in the US and Brazil, create strong tailwinds for fiscal 20224. In light of this, and subject to any uncontrollable factors, we are targeting continued strong growth in US-GAAP EBITDA and cash generation for the fiscal year ending March 2022. We are committed to delivering increasing value for our shareholders”.
Please see the link below for details
Source: ArborGen Holdings Limited
No comments yet
TGG - Response to media speculation
ARB - Annual Meeting Date and Director Nominations
CNU - Q4 FY25 Connections Update
MOVE FY25 Results and Investor Briefing 29 August 2025
RYM - First quarter trading update
July 11th Morning Report
IKE Announces equity raising of A$20 million
Chorus full year results date
FPH 2025 Notice of Annual Meeting and Voting Form
July 10th Morning Report